The diagnosis of PCa recurrence after prior definitive therapy is based on an increase in serum prostate-specific antigen (PSA); the threshold level varies by treatment, being higher for patients treated with radiation than for those treated by radical prostatectomy (3). The gene discussed is KLK3; the disease is posterior cortical atrophy.